All news

Robert Blum Submits Form 144 for Sale of 22,500 Cytokinetics Shares Acquired via Stock Options

Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash

Robert Blum, a director and officer at Cytokinetics, Incorporated, has filed a Form 144 to sell 22,500 shares of common stock. These shares, valued at

Read original source

CYTK company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.